Multicenter, double-blind, randomized, intra- individual crossover comparison of gadobenate dimeglumine and gadopentetate dimeglumine in mri of brain tumors at 3 tesla

Zoran Rumboldt, Howard A. Rowley, Fred Steinberg, Joseph A Maldjian, Jordi Ruscalleda, Lars Gustafsson, Stefano Bastianello

Research output: Contribution to journalArticle

29 Citations (Scopus)

Abstract

Purpose: To prospectively compare 0.1 mmol/kg doses of gadobenate dimeglumine and gadopentetate dimeglumine for contrast-enhanced MRI of brain lesions at 3 Tesla (T). Materials and Methods: Forty-six randomized patients underwent a first examination with gadobenate dimeglumine (n = 23) or gadopentetate dimeglumine (n = 23) and then, after 2-7 days, a second examination with the other agent. Contrast administration (volume, rate), sequence parameters (T1wSE; T1wGRE), and interval between injection and image acquisition were identical for examinations in each patient. Three blinded neuroradiologists evaluated images qualitatively (lesion delineation, lesion enhancement, global preference) and quantitatively (lesion-to-brain ratio [LBR], contrast- to-noise ratio [CNR], % lesion enhancement). Differences were assessed using Wilcoxon's signed-rank test. Reader agreement was determined using kappa (k) statistics. Results: There were no demographic differences between groups. The three readers preferred gadobenate dimeglumine globally in 22 (53.7%), 21 (51.2%), and 27 (65.9%) patients, respectively, compared with 0, 1, and 0 patients for gadopentetate dimeglumine. Similar significant (P < 0.001) preference was expressed for lesion border delineation and enhancement. Reader agreement was consistently good (k = 0.48-0.64). Significantly (P < 0.05) higher LBR (+43.5- 61.2%), CNR (+51.3-147.6%), and % lesion enhancement (+45.9-49.5%) was noted with gadobenate dimeglumine. Conclusion: Brain lesion depiction at 3T is significantly improved with 0.1 mmol/kg gadobenate dimeglumine.

Original languageEnglish (US)
Pages (from-to)760-767
Number of pages8
JournalJournal of Magnetic Resonance Imaging
Volume29
Issue number4
DOIs
StatePublished - Apr 1 2009

Fingerprint

Gadolinium DTPA
Brain Neoplasms
Brain
Noise
Nonparametric Statistics
Demography
gadobenic acid
Injections

Keywords

  • Brain tumor imaging
  • Comparative studies
  • Gadobenate dimeglu- Mine
  • High field mri

ASJC Scopus subject areas

  • Radiology Nuclear Medicine and imaging

Cite this

Multicenter, double-blind, randomized, intra- individual crossover comparison of gadobenate dimeglumine and gadopentetate dimeglumine in mri of brain tumors at 3 tesla. / Rumboldt, Zoran; Rowley, Howard A.; Steinberg, Fred; Maldjian, Joseph A; Ruscalleda, Jordi; Gustafsson, Lars; Bastianello, Stefano.

In: Journal of Magnetic Resonance Imaging, Vol. 29, No. 4, 01.04.2009, p. 760-767.

Research output: Contribution to journalArticle

Rumboldt, Zoran ; Rowley, Howard A. ; Steinberg, Fred ; Maldjian, Joseph A ; Ruscalleda, Jordi ; Gustafsson, Lars ; Bastianello, Stefano. / Multicenter, double-blind, randomized, intra- individual crossover comparison of gadobenate dimeglumine and gadopentetate dimeglumine in mri of brain tumors at 3 tesla. In: Journal of Magnetic Resonance Imaging. 2009 ; Vol. 29, No. 4. pp. 760-767.
@article{8cc8c7f405e745af811dfeeb801c390b,
title = "Multicenter, double-blind, randomized, intra- individual crossover comparison of gadobenate dimeglumine and gadopentetate dimeglumine in mri of brain tumors at 3 tesla",
abstract = "Purpose: To prospectively compare 0.1 mmol/kg doses of gadobenate dimeglumine and gadopentetate dimeglumine for contrast-enhanced MRI of brain lesions at 3 Tesla (T). Materials and Methods: Forty-six randomized patients underwent a first examination with gadobenate dimeglumine (n = 23) or gadopentetate dimeglumine (n = 23) and then, after 2-7 days, a second examination with the other agent. Contrast administration (volume, rate), sequence parameters (T1wSE; T1wGRE), and interval between injection and image acquisition were identical for examinations in each patient. Three blinded neuroradiologists evaluated images qualitatively (lesion delineation, lesion enhancement, global preference) and quantitatively (lesion-to-brain ratio [LBR], contrast- to-noise ratio [CNR], {\%} lesion enhancement). Differences were assessed using Wilcoxon's signed-rank test. Reader agreement was determined using kappa (k) statistics. Results: There were no demographic differences between groups. The three readers preferred gadobenate dimeglumine globally in 22 (53.7{\%}), 21 (51.2{\%}), and 27 (65.9{\%}) patients, respectively, compared with 0, 1, and 0 patients for gadopentetate dimeglumine. Similar significant (P < 0.001) preference was expressed for lesion border delineation and enhancement. Reader agreement was consistently good (k = 0.48-0.64). Significantly (P < 0.05) higher LBR (+43.5- 61.2{\%}), CNR (+51.3-147.6{\%}), and {\%} lesion enhancement (+45.9-49.5{\%}) was noted with gadobenate dimeglumine. Conclusion: Brain lesion depiction at 3T is significantly improved with 0.1 mmol/kg gadobenate dimeglumine.",
keywords = "Brain tumor imaging, Comparative studies, Gadobenate dimeglu- Mine, High field mri",
author = "Zoran Rumboldt and Rowley, {Howard A.} and Fred Steinberg and Maldjian, {Joseph A} and Jordi Ruscalleda and Lars Gustafsson and Stefano Bastianello",
year = "2009",
month = "4",
day = "1",
doi = "10.1002/jmri.21695",
language = "English (US)",
volume = "29",
pages = "760--767",
journal = "Journal of Magnetic Resonance Imaging",
issn = "1053-1807",
publisher = "John Wiley and Sons Inc.",
number = "4",

}

TY - JOUR

T1 - Multicenter, double-blind, randomized, intra- individual crossover comparison of gadobenate dimeglumine and gadopentetate dimeglumine in mri of brain tumors at 3 tesla

AU - Rumboldt, Zoran

AU - Rowley, Howard A.

AU - Steinberg, Fred

AU - Maldjian, Joseph A

AU - Ruscalleda, Jordi

AU - Gustafsson, Lars

AU - Bastianello, Stefano

PY - 2009/4/1

Y1 - 2009/4/1

N2 - Purpose: To prospectively compare 0.1 mmol/kg doses of gadobenate dimeglumine and gadopentetate dimeglumine for contrast-enhanced MRI of brain lesions at 3 Tesla (T). Materials and Methods: Forty-six randomized patients underwent a first examination with gadobenate dimeglumine (n = 23) or gadopentetate dimeglumine (n = 23) and then, after 2-7 days, a second examination with the other agent. Contrast administration (volume, rate), sequence parameters (T1wSE; T1wGRE), and interval between injection and image acquisition were identical for examinations in each patient. Three blinded neuroradiologists evaluated images qualitatively (lesion delineation, lesion enhancement, global preference) and quantitatively (lesion-to-brain ratio [LBR], contrast- to-noise ratio [CNR], % lesion enhancement). Differences were assessed using Wilcoxon's signed-rank test. Reader agreement was determined using kappa (k) statistics. Results: There were no demographic differences between groups. The three readers preferred gadobenate dimeglumine globally in 22 (53.7%), 21 (51.2%), and 27 (65.9%) patients, respectively, compared with 0, 1, and 0 patients for gadopentetate dimeglumine. Similar significant (P < 0.001) preference was expressed for lesion border delineation and enhancement. Reader agreement was consistently good (k = 0.48-0.64). Significantly (P < 0.05) higher LBR (+43.5- 61.2%), CNR (+51.3-147.6%), and % lesion enhancement (+45.9-49.5%) was noted with gadobenate dimeglumine. Conclusion: Brain lesion depiction at 3T is significantly improved with 0.1 mmol/kg gadobenate dimeglumine.

AB - Purpose: To prospectively compare 0.1 mmol/kg doses of gadobenate dimeglumine and gadopentetate dimeglumine for contrast-enhanced MRI of brain lesions at 3 Tesla (T). Materials and Methods: Forty-six randomized patients underwent a first examination with gadobenate dimeglumine (n = 23) or gadopentetate dimeglumine (n = 23) and then, after 2-7 days, a second examination with the other agent. Contrast administration (volume, rate), sequence parameters (T1wSE; T1wGRE), and interval between injection and image acquisition were identical for examinations in each patient. Three blinded neuroradiologists evaluated images qualitatively (lesion delineation, lesion enhancement, global preference) and quantitatively (lesion-to-brain ratio [LBR], contrast- to-noise ratio [CNR], % lesion enhancement). Differences were assessed using Wilcoxon's signed-rank test. Reader agreement was determined using kappa (k) statistics. Results: There were no demographic differences between groups. The three readers preferred gadobenate dimeglumine globally in 22 (53.7%), 21 (51.2%), and 27 (65.9%) patients, respectively, compared with 0, 1, and 0 patients for gadopentetate dimeglumine. Similar significant (P < 0.001) preference was expressed for lesion border delineation and enhancement. Reader agreement was consistently good (k = 0.48-0.64). Significantly (P < 0.05) higher LBR (+43.5- 61.2%), CNR (+51.3-147.6%), and % lesion enhancement (+45.9-49.5%) was noted with gadobenate dimeglumine. Conclusion: Brain lesion depiction at 3T is significantly improved with 0.1 mmol/kg gadobenate dimeglumine.

KW - Brain tumor imaging

KW - Comparative studies

KW - Gadobenate dimeglu- Mine

KW - High field mri

UR - http://www.scopus.com/inward/record.url?scp=65249130593&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=65249130593&partnerID=8YFLogxK

U2 - 10.1002/jmri.21695

DO - 10.1002/jmri.21695

M3 - Article

VL - 29

SP - 760

EP - 767

JO - Journal of Magnetic Resonance Imaging

JF - Journal of Magnetic Resonance Imaging

SN - 1053-1807

IS - 4

ER -